Abstract |
Uracil and tegafur (in a molar ratio of 4: 1 [UFT]) plus calcium folinate comprise the components of the oral agent, Orzel, which appears to have activity comparable to intravenously administered 5-fluorouracil. This article describes the design of an open-label, disease-oriented, phase I trial of UFT plus calcium folinate in combination with simultaneous pelvic radiation for recurrent rectal cancer. This trial is designed to determine the maximum tolerated dose and dose-limiting toxicity of this regimen.
|
Authors | W Hoffmann, M Schiebe, J Dethling, C Martin |
Journal | Oncology (Williston Park, N.Y.)
(Oncology (Williston Park))
Vol. 13
Issue 7 Suppl 3
Pg. 125-6
(Jul 1999)
ISSN: 0890-9091 [Print] United States |
PMID | 10442380
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Tegafur
- Uracil
- Leucovorin
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Follow-Up Studies
- Humans
- Leucovorin
(therapeutic use)
- Neoplasm Recurrence, Local
- Radiotherapy, Adjuvant
- Rectal Neoplasms
(drug therapy, radiotherapy)
- Safety
- Tegafur
(therapeutic use)
- Treatment Outcome
- Uracil
(therapeutic use)
|